<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655222</url>
  </required_header>
  <id_info>
    <org_study_id>DE-PEG-11650</org_study_id>
    <nct_id>NCT04655222</nct_id>
  </id_info>
  <brief_title>Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program</brief_title>
  <official_title>Non-interventional Safety Study to Investigate Pregnancy Outcomes in Female Patients Exposed to SC Peginterferon Beta-1a and IM Interferon Beta-1a Reported in a German Patient Support Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective(s) of the study is to evaluate the impact of exposure to SC&#xD;
      Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy&#xD;
      outcome in female participants who had registered in the German Patient Support Program (PSP)&#xD;
      and of whom a pregnancy report and pregnancy outcome report is available.&#xD;
&#xD;
      The secondary objectives of this study are applicable for a subpopulation of the&#xD;
      above-mentioned population, i.e. for participants of whom data on a standardized&#xD;
      questionnaire collected during a telephone interview is available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study with focus on existing pregnancy reporting forms&#xD;
      (retrospective part) and a patient's questionnaire which is completed at a single point of&#xD;
      time (prospective part). Main data source for the retrospective data (from 2014 until&#xD;
      December 2019) will be captured from multiple sclerosis service-center (MSSC) database, i.e.&#xD;
      the entered pregnancy report (to be completed as soon as pregnancy becomes known) and&#xD;
      pregnancy outcomes report (to be completed after completion of pregnancy).&#xD;
&#xD;
      Prospective data (December 2020 to 31 March 2021) will be captured as standardized ePDF&#xD;
      questionnaire completed during telephone interview. If the pregnancy report or the pregnancy&#xD;
      outcome report is incomplete, i.e. the data above was not collected, the open questions will&#xD;
      be addressed during a telephone interview performed by the MSSC and the new information will&#xD;
      be entered into the MSCC database. The patient questionnaire will be completed at a single&#xD;
      point of time during the telephone interview performed by the MSSC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Actual">October 15, 2021</completion_date>
  <primary_completion_date type="Actual">October 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Live Births Without Congenital Anomalies</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Live Births With Congenital Anomalies</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Ectopic Pregnancies</measure>
    <time_frame>8 weeks of gestation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Spontaneous Abortions</measure>
    <time_frame>up to 22 weeks of gestation</time_frame>
    <description>A spontaneous abortion is defined as fetal death before 22 weeks of gestation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elective Abortions</measure>
    <time_frame>up to Week 20 of gestation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Preterm Births</measure>
    <time_frame>up to 37 weeks of gestation</time_frame>
    <description>A preterm birth is a birth before 37 completed weeks of gestation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Stillbirths</measure>
    <time_frame>from 22 week up to 39 weeks of gestation</time_frame>
    <description>A still birth is defined as fetal death at &gt;22 weeks gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Weight of the Children</measure>
    <time_frame>From Birth up to Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Length of the Children</measure>
    <time_frame>From Birth up to Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Head Circumference of the Children</measure>
    <time_frame>From Birth up to Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Abnormalities Diagnosed During Pediatric Check-ups</measure>
    <time_frame>up to Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Women Discontinued Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancy</measure>
    <time_frame>up to 39 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancy</measure>
    <time_frame>up to 39 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Women Starting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancy</measure>
    <time_frame>up to 39 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancy</measure>
    <time_frame>up to 39 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Women Restarting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy After Birth</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Restart Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Birth</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Women Starting Another Multiple Sclerosis (MS) Therapy During/After Pregnancy</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start Another MS Therapy During/After Pregnancy in Relation to Birth</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Women Using Other Therapies During Pregnancy</measure>
    <time_frame>up to 39 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Multiple Sclerosis Relapses in Women with Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Before, During and After Pregnancy</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Expanded Disability Status Scale (EDSS) During and After Pregnancy to Expanded Disability Status Scale (EDSS) Before Pregnancy</measure>
    <time_frame>Week 0 up to Week 39 of gestation</time_frame>
    <description>EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in multiple sclerosis (MS). Scores range from 0.0 (normal) to 10.0 (death due to MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Women Breastfeeding Under Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Exposed Breastfeeding</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Multiple Sclerosis (MS) Relapse After Introduction of the First Supplemental Feedings in Women With Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Lactation</measure>
    <time_frame>up to end of study (4 months)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">470</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <description>Pregnant Multiple Sclerosis (MS) participants treated with SC interferon beta therapy or an IM interferon beta therapy in the German PSP of the MSSC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Beta Therapy</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All female participants treated with SC Peginterferon beta-1a therapy or IM Interferon&#xD;
        beta-1a therapy who fulfil the inclusion criteria are eligible to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed relapsing-remitting multiple sclerosis (RRMS) or clinically isolated&#xD;
             syndrome (CIS) (CIS indication only applicable for interferon beta-1a)&#xD;
&#xD;
          -  Exposure to either SC Peginterferon beta-1a therapy or an IM Interferon beta-1a&#xD;
             therapy before or during pregnancy&#xD;
&#xD;
          -  Registered in the PSP of the multiple sclerosis service- center (MSSC) and agreed in&#xD;
             writing to the privacy policy of the registration form&#xD;
&#xD;
          -  Reported pregnancy data (pregnancy report and pregnancy outcome report) available at&#xD;
             MSSC. Note: only pregnancy data (i.e. obtained until 15 October 2020) will be&#xD;
             considered.&#xD;
&#xD;
          -  Pregnancy outcome in the retrospectively collected data was a live birth&#xD;
&#xD;
        Exclusion Criteria: Any criteria that does not fulfil the above-mentioned inclusion&#xD;
        criteria.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GÃ¶ttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

